Clinical Trial

PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment

Study acronym: PANORAMIX
Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The main objective of PANORAMIX phase II trial is to optimize first-lie (L1) NALIRIFOX treatment for pancreatic cancer through the implementation of 5-fluorouracil (5-FU) maintenance therapy. Additionally, it aims to investigate the role of antibiotics and microbiota in second-line (L2) treatment.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-11.
Trial Details
NCT Number NCT07028424
Lead Sponsor GERCOR - Multidisciplinary Oncology Cooperative Group
Collaborators: Servier
Conditions PDAC - Pancreatic Ductal Adenocarcinoma
Enrollment 206 participants
Start Date 2025-07
Primary Completion 2029-07 (estimated)
Study Completion 2030-12 (estimated)
Updated on ClinicalTrials.gov 2025-07-01